CIPLA | BH.IMMUN&BIO | CIPLA/ BH.IMMUN&BIO |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 30.1 | -7.8 | - | View Chart |
P/BV | x | 4.8 | 1.5 | 314.8% | View Chart |
Dividend Yield | % | 0.6 | 0.0 | - |
CIPLA BH.IMMUN&BIO |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CIPLA Mar-23 |
BH.IMMUN&BIO Mar-23 |
CIPLA/ BH.IMMUN&BIO |
5-Yr Chart Click to enlarge
|
||
High | Rs | 1,185 | 52 | 2,288.0% | |
Low | Rs | 852 | 21 | 4,156.1% | |
Sales per share (Unadj.) | Rs | 281.9 | 10.3 | 2,728.6% | |
Earnings per share (Unadj.) | Rs | 35.1 | -3.9 | -911.7% | |
Cash flow per share (Unadj.) | Rs | 49.7 | -3.8 | -1,304.2% | |
Dividends per share (Unadj.) | Rs | 8.50 | 0 | - | |
Avg Dividend yield | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 289.2 | 20.4 | 1,415.8% | |
Shares outstanding (eoy) | m | 807.15 | 43.18 | 1,869.3% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.6 | 3.5 | 103.3% | |
Avg P/E ratio | x | 29.0 | -9.4 | -309.1% | |
P/CF ratio (eoy) | x | 20.5 | -9.5 | -216.1% | |
Price / Book Value ratio | x | 3.5 | 1.8 | 199.0% | |
Dividend payout | % | 24.2 | 0 | - | |
Avg Mkt Cap | Rs m | 822,164 | 1,561 | 52,670.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 38,301 | 151 | 25,289.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 227,531 | 446 | 51,005.7% | |
Other income | Rs m | 5,121 | 11 | 48,314.2% | |
Total revenues | Rs m | 232,653 | 457 | 50,943.2% | |
Gross profit | Rs m | 48,079 | -161 | -29,920.2% | |
Depreciation | Rs m | 11,721 | 2 | 586,055.0% | |
Interest | Rs m | 1,095 | 71 | 1,551.6% | |
Profit before tax | Rs m | 40,384 | -223 | -18,135.2% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 12,029 | -56 | -21,369.0% | |
Profit after tax | Rs m | 28,355 | -166 | -17,041.2% | |
Gross profit margin | % | 21.1 | -36.0 | -58.7% | |
Effective tax rate | % | 29.8 | 25.3 | 117.8% | |
Net profit margin | % | 12.5 | -37.3 | -33.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 168,051 | 358 | 46,937.6% | |
Current liabilities | Rs m | 50,333 | 940 | 5,352.2% | |
Net working cap to sales | % | 51.7 | -130.6 | -39.6% | |
Current ratio | x | 3.3 | 0.4 | 877.0% | |
Inventory Days | Days | 73 | 85 | 85.8% | |
Debtors Days | Days | 7 | 1,135 | 0.6% | |
Net fixed assets | Rs m | 117,318 | 1,262 | 9,297.0% | |
Share capital | Rs m | 1,614 | 432 | 373.9% | |
"Free" reserves | Rs m | 231,845 | 450 | 51,482.3% | |
Net worth | Rs m | 233,460 | 882 | 26,465.1% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 290,067 | 1,620 | 17,906.3% | |
Interest coverage | x | 37.9 | -2.2 | -1,757.9% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.8 | 0.3 | 284.8% | |
Return on assets | % | 10.2 | -5.9 | -171.7% | |
Return on equity | % | 12.1 | -18.9 | -64.4% | |
Return on capital | % | 17.8 | -17.2 | -103.1% | |
Exports to sales | % | 22.6 | 0 | - | |
Imports to sales | % | 8.9 | 14.5 | 61.4% | |
Exports (fob) | Rs m | 51,516 | NA | - | |
Imports (cif) | Rs m | 20,202 | 65 | 31,310.9% | |
Fx inflow | Rs m | 64,282 | 0 | - | |
Fx outflow | Rs m | 20,202 | 65 | 31,310.9% | |
Net fx | Rs m | 44,080 | -65 | -68,319.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 32,377 | 109 | 29,725.0% | |
From Investments | Rs m | -23,885 | 5 | -516,993.5% | |
From Financial Activity | Rs m | -9,583 | -147 | 6,513.7% | |
Net Cashflow | Rs m | -968 | -34 | 2,882.9% |
Indian Promoters | % | 13.4 | 59.3 | 22.7% | |
Foreign collaborators | % | 20.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 50.2 | 0.0 | - | |
FIIs | % | 25.8 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 66.5 | 40.8 | 163.3% | |
Shareholders | 436,154 | 35,313 | 1,235.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare CIPLA With: DIVIS LABORATORIES SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Cipla | BH.IMMUN&BIO | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.92% | -2.55% | -0.24% |
1-Month | -6.67% | 6.13% | -0.33% |
1-Year | 52.43% | 31.40% | 53.41% |
3-Year CAGR | 15.49% | -11.59% | 14.82% |
5-Year CAGR | 19.87% | 31.43% | 19.73% |
* Compound Annual Growth Rate
Here are more details on the Cipla share price and the BH.IMMUN&BIO share price.
Moving on to shareholding structures...
The promoters of Cipla hold a 33.5% stake in the company. In case of BH.IMMUN&BIO the stake stands at 59.3%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Cipla and the shareholding pattern of BH.IMMUN&BIO.
Finally, a word on dividends...
In the most recent financial year, Cipla paid a dividend of Rs 8.5 per share. This amounted to a Dividend Payout ratio of 24.2%.
BH.IMMUN&BIO paid Rs 0.0, and its dividend payout ratio stood at -0.0%.
You may visit here to review the dividend history of Cipla, and the dividend history of BH.IMMUN&BIO.
For a sector overview, read our pharmaceuticals sector report.
Asian stocks got off to a positive start on Monday ahead of the Federal Reserve's policy meeting later in the week.